RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC)
Sclafani, Francesco, Gonzalez, David, Cunningham, David, Hullki Wilson, Sanna, Peckitt, Clare, Tabernero, Josep, Glimelius, Bengt, Cervantes, Andres, Wotherspoon, Andrew, Brown, Gina, Tait, Diana M., Oates, Jacqueline Rose, Chau, Ian
Published in Journal of clinical oncology (20.01.2014)
Published in Journal of clinical oncology (20.01.2014)
Get full text
Journal Article
Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial
Sclafani, Francesco, Gonzalez, David, Cunningham, David, Hullki Wilson, Sanna, Peckitt, Clare, Tabernero, Josep, Glimelius, Bengt, Cervantes, Andres, Wotherspoon, Andrew, Dewdney, Alice, Brown, Gina, Tait, Diana M., Oates, Jacqueline Rose, Chau, Ian
Published in Journal of clinical oncology (20.01.2014)
Published in Journal of clinical oncology (20.01.2014)
Get full text
Journal Article
Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial
Sclafani, Francesco, Chau, Ian, Cunningham, David, Lampis, Andrea, Hahne, Jens, Braconi, Chiara, Peckitt, Clare, Gonzalez, David, Hullki Wilson, Sanna, Capdevila, Jaume, Glimelius, Bengt, Cervantes, Andres, Begum, Ruwaida, Brown, Gina, Tait, Diana M., Wotherspoon, Andrew, Eltahir, Zakaria, Yusuf-Adam, Sandra, Oates, Jacqueline Rose, Valeri, Nicola
Published in Journal of clinical oncology (20.01.2015)
Published in Journal of clinical oncology (20.01.2015)
Get full text
Journal Article